Glycans in Blood Homeostasis and Disease

血液稳态和疾病中的聚糖

• 批准号: 9519462
• 负责人: Nancy M. Dahms
• 金额: $ 97.8万
• 依托单位: VERSITI WISCONSIN, INC.
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-07-01 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9519462
• 关键词: Address; Adult; Affect; Applications Grants; Area; Basic Science; Benign; Biochemistry; Biology; Blood; Blood Platelets; Blood Vessels; Childhood; Clinical; Communication; Discipline; Disease; Environment; Enzymes; Faculty; Fertilization; Foundations; Future; Future Generations; Generations; Glycobiology; Glycosaminoglycans; Hematological Disease; Hematology; Hematopoiesis; Hemostatic function; Homeostasis; Immunology; Inflammation; Investigation; Language; Leadership; Lysosomal Storage Diseases; Mainstreaming; Medical; Medicine; Mentors; Mentorship; Mission; National Heart, Lung, and Blood Institute; Patient Care; Pharmaceutical Chemistry; Polysaccharides; Positioning Attribute; Program Development; Publications; Research; Research Personnel; Role; SECTM1 gene; Scientist; Structure; Systems Biology; Thinking; Thrombopoiesis; Training; Transfusion; United States National Institutes of Health; Work; career; career development; clinical translation; improved; member; programs; receptor binding; response; skill acquisition; translational medicine

PROJECT SUMMARY In response to the urgent need to “transform and democratize glycosciences from a super-specialized research domain into the mainstream of biology and clinical translation such that glycans become an integral component of future scholars'/investigators' scientific thinking”, we present a unique, multi-PI, multi-center K12 career development program referred to as Program for Medical GlycoSciences. This Program will address this need with one-on-one and team-mentorship approaches to enable emerging generations of researchers to acquire the strongest possible foundation in pursuing basic and applied glycobiology of relevance to hematologic disorders. The 23-member Program Faculty is comprised of 1) clinicians trained in benign hematology, transfusion medicine, immunology, and lysosomal storage diseases, and 2) basic scientists with diverse expertise in biochemistry of glycosaminoglycans (GAGs), glycan-binding receptors, glycan-modifying enzymes, medicinal chemistry, and systems biology. The Program Faculty will work together to generate a common “glyco-clinical” language that will allow cross-communication and fertilization between clinical and basic researchers to train future generations of glyco-clinical scientists. This Program will achieve this mission by seamlessly combining four major areas of investigation: 1) `Glycans In Hematopoiesis, Thrombopoiesis, Platelets, And Vascular Biology'; 2) `Lysosomal Enzyme Function', 3) `Glycans In Lineage Fate Decision And In End Effector Functions'; 4) GAGs In Hemostasis, Hematopoiesis And Inflammation'. The Specific Aims of this Program are: 1. To identify and train ten exceptionally qualified Scholars in glycochemistry/glycobiology within context of adult/pediatric benign hematology, transfusion medicine or in clinical disciplines relating to the mission of the NHLBI, in a structured, mentored and protected environment. Each Scholar will receive 2 – 3 years of glycoscience skills development that focuses on acquisition, interpretation and publication of research, enabling federal (NIH/NSF) grant applications for transition to an independent academic position. 2. To seamlessly integrate clinically trained Scholars into glycosciences and basic science Scholars into translational medicine to affect efficient transfer of emerging glyco-concepts from bench to improved patient care. 3. To provide a structured environment such that at the end of the program, the majority of K12 Scholars will be: a) initiated in an academic glycoscience career, and b) at the cusp of leadership roles in translational glycoscience preferentially in adult/pediatric benign hematology, transfusion medicine or in clinical disciplines relating to the mission of the NHLBI.

项目摘要 应对迫切需要“从超级特殊研究中转化和民主化糖基镜 域进入生物学和临床翻译的主流，使聚糖成为不可或缺的组成部分 关于未来学者/调查人员的科学思维”，我们提出了独特的，多PI的多中心K12职业 开发计划称为医学糖基镜计划。这个程序将解决这个问题 需要一对一和团队训练的方法，使新兴的研究人员能够 获得强大的基础，以追求与 血液学疾病。由23名成员的课程教师包括1）接受良性培训的临床医生 血液学，输血医学，免疫学和溶酶体储存疾病，以及2）基础科学家 糖胺聚糖（GAGS），聚糖结合受体的生物化学方面的多元化专业知识，聚糖修饰 酶，药物化学和系统生物学。该计划教师将共同努力 常见的“糖临床”语言，将允许临床和 基础研究人员培训子孙后代的基础科学家。该计划将实现此任务 通过无缝将四个主要投资领域结合在一起：1）`造造血，血栓形成的聚糖， 血小板和血管生物学'; 2）“溶酶体酶功能”，3）`宗族命运决定和 最终效应器函数'; 4）止血，造血和炎症中的堵嘴'。具体目的 该程序是： 1。识别和培训十个在糖化学/糖生物学领域具有特殊资格的学者 成人/小儿良性血液学，输血医学或与使命有关的临床学科 NHLBI在结构化，修补和受保护的环境中。每个学者将获得2 - 3年的 侧重于获取，解释和发表研究的糖科学技能开发， 启用联邦（NIH/NSF）授予申请，以过渡到独立的学术职位。 2。将经过临床训练的学者无缝整合到糖基础和基础科学学者中 转化医学以影响新兴的糖概念从板凳到改进的有效转移 病人护理。 3。提供一个结构化的环境，以便在计划结束时，大多数K12学者将 BE：a）在学术性两种科学生涯中发起，b）在转化领域的领导角色中 在成人/小儿血液学，输血医学或临床上优先进行糖科学 与NHLBI任务有关的学科。